A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Summary

This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.

Timeline

Start

2026-04-03

Primary completion

2028-03

Completion

2028-11

Drugs

Indications